Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.42 |
| ▸ | RELA | Q04206 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924096 | 0.92 | SMN1; SMN2 (0.44) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL923951 | 0.78 | KIF11 (0.41) | — | |
| SCHEMBL924073 | 0.77 | ADORA1 (0.45) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL924072 | 0.77 | ADORA1 (0.45) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL15782947 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL922383 | 0.72 | RAPGEF4 (0.38) | MAPTRAB9ANPC1GAAMEN1 | |
| SCHEMBL924332 | 0.72 | MAPT (0.46) | SMN1; SMN2MAPTRAB9ANPC1GAA | |
| SCHEMBL2479413 | 0.70 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL378949 | 0.69 | SMN1; SMN2 (0.62) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL921999 | 0.69 | ALDH1A1 (0.46) | MAPTRAB9ANPC1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | claimed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | claimed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | claimed |
| US-6436915-B1 | ANTIPROLIFERATIVE AND ANTITUMOR AGENTS AND ANGIOGENESIS INHIBITORS | KINETEK PHARMACEUTICALS, INC. (CA) | 2002-08-20 | — | — | US | claimed |
| US-20020042501-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2002-04-11 | — | — | US | claimed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-7105503-B2 | Pyrazole compounds | QLT INC. (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | disclosed |
| EP-1276723-A2 | PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY | Kinetek Pharmaceuticals, Inc. (CA) | 2003-01-22 | — | — | EP | disclosed |
| US-6436915-B1 | ANTIPROLIFERATIVE AND ANTITUMOR AGENTS AND ANGIOGENESIS INHIBITORS | KINETEK PHARMACEUTICALS, INC. (CA) | 2002-08-20 | — | — | US | disclosed |
| US-20020042501-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001077080-A2 | PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY | KINETEK PHARMACEUTICALS, INC. (CA) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | SMN1; SMN2 4161/4885MAPT 4573/4885RAB9A 4545/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | SMN1; SMN2 4161/4885MAPT 4573/4885RAB9A 4545/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | SMN1; SMN2 2243/4885MAPT 4000/4885RAB9A 3555/4885 |
| US-20030060453-A1 | Pyrazole compounds | CCNC, MKI67, CDC25C | SMN1; SMN2 3557/4885MAPT 4486/4885RAB9A 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.